1.Effect of plasma fibrinogen concentration on stroke recurrence within one year of first-ever ischemic stroke: a prospective case series study
Lili JI ; Donglin HAO ; Aijin MA ; Lechao LI ; Yanfang ZHANG ; Qing DI
International Journal of Cerebrovascular Diseases 2013;(4):277-281
Objective To investigate the effect of plasma fibrinogen (Fib) level on stroke recurrence within one year of first-ever ischemic stroke.Methods The patients with first-ever acute ischemic stroke were enrolled prospectively and were followed up for at least one year.They were divided into either a recurrent group or a non-recurrent group.Multivariate logistic regression analysis was used to explore the risk factors for stroke recurrence within one year of first-ever ischemic stroke.According to the plasma Fib levels of the early onset,the patients were divided into a high Fib group and a normal Fib group.Kaplan-Meier survival analysis was used to compare the recurrence between the two groups.Results A total of 121 patients with first-ever acute ischemic stroke were enrolled,111 completed one year follow up,and 30 of them (27.027%) had recurrent stroke.Multivariatelogistic regression analysis showed that the increased plasma Fib level (odds ratio [OR] 13.238,95% confidence interval [CI] 1.152-152.077; P=0.038),older at the first onset (OR 1.321,95% CI1.064-1.641;P=0.012),high body mass index(OR 1.351,95% CI 1.001-1.823; P=0.049),and poor compliance of antiplatelet drugs (OR 36.819,95% CI 1.890-717.143; P=0.017) and antihypertensive drugs (OR 50.765,95% CI 3.198-805.878; P =0.005) were the dependent the risk factors for stroke recurrence within one year of first-ever ischemic stroke.Kaplan-Meier survival function curves showed that the recurrence rate of stroke in the high Fib group was significantly higher than that in the normalFib group (Log-rank test,P =0.000).Conclusions The increased high plasma Fib level,advanced age,obesity,as well as poor compliance of antiplatelet drugs and antihypertensive drugs were the independent risk factors for stroke recurrence within one year of first-ever ischemic stroke.